Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | PTGIR | P43119 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294267 | 1.00 | SIGMAR1 (0.54) | SIGMAR1SMN1; SMN2TSHRLTA4HPTGIR | |
| Hydrochloric Acid SCHEMBL2236752 | 0.92 | SIGMAR1 (0.56) | SIGMAR1SMN1; SMN2TSHRLTA4HPTGIR | |
| SCHEMBL2231787 | 0.89 | CXCR4 (0.59) | SIGMAR1TSHRLTA4HHRH3 | |
| SCHEMBL2232165 | 0.89 | CXCR4 (0.59) | SIGMAR1TSHRLTA4HHRH3 | |
| SCHEMBL2231797 | 0.89 | TSHR (0.54) | SIGMAR1SMN1; SMN2TSHRLTA4HHRH3 | |
| SCHEMBL592479 | 0.88 | SIGMAR1 (0.67) | SIGMAR1SMN1; SMN2PTGIRHRH3 | |
| Hydrochloric Acid SCHEMBL2233324 | 0.88 | CXCR4 (0.58) | SIGMAR1TSHRLTA4HHRH3 | |
| SCHEMBL2231202 | 0.87 | DRD2 (0.53) | SIGMAR1TSHRLTA4HHRH3 | |
| SCHEMBL2233553 | 0.87 | LTA4H (0.50) | SIGMAR1TSHRLTA4HHRH3 | |
| SCHEMBL2232773 | 0.87 | MLNR (0.53) | SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2528897-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| WO-2011093524-A9 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011093524-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | SIGMAR1 1422/4885SMN1; SMN2 4081/4885TSHR 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.